ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

Both my parents use CPAP machines to treat their sleep apnea so I worked with my 59-year ... but there are also bundles for ResMed AirSense 10 ($339), Fisher & Paykel ICON ($339), and others.

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

ResMed's share price has outperformed the S ... on the potential impact of GLP-1 weight-loss drugs on obstructive sleep apnea (‘OSA’) prevalence, and the negative influence that widespread ...

ResMed (NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst ...